Imugene Seeks ASX Quotation for 27.6 Million New Shares
Imugene shareholders back capital-raising resolutions at extraordinary meeting
Waters partners with IMU Biosciences to advance AI immune mapping platform
Imugene (IUGNF) Receives a Buy from Bell Potter
Imugene Cuts Potential Dilution as Expired Options and Rights Lapse